Search Results

Jaguar Health, Inc. today announced that on June 25, 2024 the Company received formal notice from The Nasdaq Stock Market LLC that Jaguar has regained compliance with Nasdaq’s minimum bid price requirement.

Jaguar Health, Inc. announced the voting results of the Company’s Annual Meeting of Stockholders held June 21, 2024.

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today reported consolidated first-quarter 2024 financial results and provided Company updates.

Jaguar Health, Inc. today announced that Massimo Radaelli, PhD, has been appointed President of Jaguar International.

Jaguar Health, Inc. today announced that the company’s out-licensing agreement with Magdalena Biosciences, Inc. (“Magdalena”), the joint venture formed by Jaguar and Filament Health Corp.

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today reported consolidated financial results for the year ended December 31, 2023.

Jaguar Health, Inc. today announced that the results of a third-party, investigator-initiated study of crofelemer, Napo’s novel plant-based prescription drug, show that twice daily oral administration of crofelemer led to a statistically meaningful reduction of abdominal pain and discomfort and improved stool consistency in functional diarrhea patients.

Jaguar Health, Inc. announced that, effective June 4, 2024, the Company granted 1,111 restricted stock units to one new employee.